🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesHas anyone dealt with fasting insulin levels?

Has anyone dealt with fasting insulin levels?

kim_atl_prep Sun, Aug 4, 2024 at 4:02 PM 14 replies 2,069 viewsPage 1 of 3
This thread is more than 22 months old. Information may be outdated. Consider searching for more recent discussions.
kim_atl_prep
Member
312
1,345
Aug 2024
Atlanta, GA
Aug 4, 2024 at 4:02 PM#1

A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

What I am trying to establish is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner.

Not looking for reassurance. Looking for the part I have got wrong.

19 14PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 16 others
Reply Quote Save Share Report
PharmD_Rodriguez
Senior Member
3,456
14,567
Jan 2024
Miami, FL
Aug 4, 2024 at 6:23 PM#2
kim_atl_prep said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

My labs after 9 months on glycaemic control: A1C 5.7%, fasting glucose 77 mg/dL, fasting insulin 8 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 6.9% and fasting glucose was 132 mg/dL. The improvement has been dramatic and consistent.

18 13TinaHashiRN, robert_kc, dan_philly and 15 others
Reply Quote Save Share Report
TomTeleRx
Member
189
678
Feb 2025
Delaware
Aug 4, 2024 at 8:44 PM#3
PharmD_Rodriguez said:
My labs after 9 months on glycaemic control: A1C 5.7%, fasting glucose 77 mg/dL, fasting insulin 8 uIU/mL.

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 42% to 21%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

Last edited: Aug 4, 2024 at 9:44 PM
17 12LibrarianMeg, bri_stats, pete_manc_UK and 14 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
tony_orlando
Member
234
1,123
Nov 2024
Orlando, FL
Aug 4, 2024 at 11:05 PM#4
kim_atl_prep said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

Adding a me-too, because a thread of one person's experience is not much use.

Last edited: Aug 5, 2024 at 12:05 AM
16 11CanadaChris, ZaraB_AL, JakeSmashed95 and 13 others
Reply Quote Save Share Report
rachel_ABQ
Member
178
890
Dec 2024
Albuquerque, NM
Aug 5, 2024 at 1:08 PM#5

From the other side of the consultation, briefly.

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)1261009084
Insulin (fasting)2214107
HOMA-IR4.54.21.81.5
Uric Acid8.96.65.75.2

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 4.5 to near 1.0 is a metabolic transformation.

15 10Dr.CardioMD, EndoResFellow, PharmacoVig_BOS and 12 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register